Zuzanna Zambrowska
Research Subjects
Zuzanna Zambrowska has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Paterek
Department of Clinical Physiology, Centre of Postgraduate Medical Education, Warsaw, Poland
1 shared publication - Marta Oknińska
Department of Clinical Physiology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland
1 shared publication - Michał Mączewski
Department of Clinical Physiology, Centre of Postgraduate Medical Education, 99/103 Marymoncka Str., 01-813 Warsaw, Poland
1 shared publication - Urszula Mackiewicz
Department of Clinical Physiology, Centre of Postgraduate Medical Education, Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 15 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (20) , 4732
Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe?
Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation remain an ongoing clinical problem and their prevention and treatment require optimization. Conventional antiarrhythmic drugs are associated with significant proarrhythmic effects that often outweigh their benefits. Another option, the implantable cardioverter defibrillator, though clearly the primary therapy for patients at high risk of ventricular arrhythmias, is costly, invasive, and requires regular monitoring. Thus there is a clear need for new antiarrhythmic treatment strategies. Ivabradine, a heartrate-reducing agent, an inhibitor of HCN channels, may be one of such options. In this review we discuss emerging data from experimental studies that indicate new mechanism of action of this drug and further areas of investigation and potential use of ivabradine as an antiarrhythmic agent. However, clinical evidence is limited, and the jury is still out on effects of ivabradine on cardiac ventricular arrhythmias in the clinical setting.
- 15 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (20) , 4732
Open AccessEffect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe?
Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation remain an ongoing clinical problem and their prevention and treatment require optimization. Conventional antiarrhythmic drugs are associated with significant proarrhythmic effects that often outweigh their benefits. Another option, the implantable cardioverter defibrillator, though clearly the primary therapy for patients at high risk of ventricular arrhythmias, is costly, invasive, and requires regular monitoring. Thus there is a clear need for new antiarrhythmic treatment strategies. Ivabradine, a heartrate-reducing agent, an inhibitor of HCN channels, may be one of such options. In this review we discuss emerging data from experimental studies that indicate new mechanism of action of this drug and further areas of investigation and potential use of ivabradine as an antiarrhythmic agent. However, clinical evidence is limited, and the jury is still out on effects of ivabradine on cardiac ventricular arrhythmias in the clinical setting.